The Effects of Vitamin D on Kynurenine Level in Children With Attention Deficit Hyperactivity Disorder: An Epidemiological Study

Document Type: Original Article


1 Faculty of Basic Sciences, Islamic Azad University of Shahrekord Branch, Shahrekord, Iran

2 Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Sahrekord, Iran

3 Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran


Background and aims: Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric disorders with a worldwide prevalence of 5%. The prevalence is even higher among school age children ranging from 8% to 12%. ADHD is predominantly childhood-onset disorder and can persist into adolescence and adulthood to inflict long-term harm. The aim of this study was to identify the epidemiological features of ADHD and investigate the effects of vitamin D on kynurenine level in children with ADHD in Iran using ELISA method.
Methods: A case-control study was designed. The study participants consisted of 40 patients with ADHD and 40 healthy participants as control group. It was conducted in Isfahan Hasht Behesht hospital from July to November 2015. All samples were treated with 1000 U of vitamin D as a tablet twice daily. The level of kynurenine was measured in blood samples using enzyme-linked immunosorbent assay (ELISA) method. Data analysis was done using SPSS software.
Results: The results of this study showed that the mean vitamin D levels were 49.73 and 73.72, respectively before and after treatment in patient group, which seem significant. The mean vitamin D level after treatment was higher in patient group in comparison with control group. On the other hand, the mean kynurenine levels were 608.1 and 662.9, respectively before and after treatment in patient group. The mean kynurenine level was the same before and after treatment.
Conclusion: According to the results of the study, we can conclude that vitamin D did not have a significant effect on kynurenine level in children with ADHD.



1. Poelmans G, Pauls DL, Buitelaar JK, Franke B. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry. 2011;168(4):365-77. doi: 10.1176/ appi.ajp.2010.10070948.

2. Farokhzadi F, Mohammadi MR, Salmanian M. Discriminant of validity the Wender Utah rating scale in Iranian adults. Acta Med Iran. 2014;52(5):360-9.

3. Kenemans JL, Bekker EM, Lijffijt M, Overtoom CC, Jonkman LM, Verbaten MN. Attention deficit and impulsivity: selecting, shifting, and stopping. Int J Psychophysiol. 2005;58(1):59-70. doi: 10.1016/j.ijpsycho.2005.03.009.

4. Querne L, Berquin P. Distinct response time distributions in attention deficit hyperactivity disorder subtypes. J Atten Disord. 2009;13(1):66-77. doi: 10.1177/1087054708323006.

5. Franke B, Neale BM, Faraone SV. Genome-wide association studies in ADHD. Hum Genet. 2009;126(1):13-50. doi: 10.1007/s00439-009-0663-4.

6. Drtilkova I, Sery O, Theiner P, Uhrova A, Zackova M, Balastikova B, et al. Clinical and molecular-genetic markers of ADHD in children. Neuro Endocrinol Lett. 2008;29(3):320-7.

7. Lasky-Su J, Neale BM, Franke B, Anney RJ, Zhou K, Maller JB, et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet. 2008;147b(8):1345-54. doi: 10.1002/ajmg.b.30867.

8. Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, et al. Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011. J Am Acad Child Adolesc Psychiatry. 2014;53(1):34-46.e2. doi: 10.1016/j.jaac.2013.09.001.

9. Coolidge FL, Thede LL, Young SE. Heritability and the comorbidity of attention deficit hyperactivity disorder with behavioral disorders and executive function deficits: a preliminary investigation. Dev Neuropsychol. 2000;17(3):273- 87. doi: 10.1207/s15326942dn1703_1.

10. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51- 90. doi: 10.1007/s00439-009-0694-x.

11. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313-23. doi: 10.1016/j.biopsych.2004.11.024.

12. Ardalan G, Farhud D, Shahmohammadi D. Hyperactivity, attention and concentration deficit in preschool children. Iran J Pediatr. 2002;12(4):53-6.

13. Hebrani P, Abdolahian E, Behdani F, Vosoogh I, Javanbakht A. The prevalence of attention deficit hyperactivity disorder in preschool-age children in Mashhad, north-East of Iran. Arch Iran Med. 2007;10(2):147-51. doi: 07102/aim.004.

14. Boomsma DI, Saviouk V, Hottenga JJ, Distel MA, de Moor MH, Vink JM, et al. Genetic epidemiology of attention deficit hyperactivity disorder (ADHD index) in adults. PLoS One. 2010;5(5):e10621. doi: 10.1371/journal.pone.0010621.

15. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21-30. doi: 10.1016/j.jchemneu.2004.08.006.

16. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. 2008;13(1):6-20.

17. Goksugur SB, Tufan AE, Semiz M, Gunes C, Bekdas M, Tosun M, et al. Vitamin D status in children with attention-deficit-hyperactivity disorder. Pediatr Int. 2014;56(4):515-9. doi: 10.1111/ped.12286.

18. Tolppanen AM, Sayers A, Fraser WD, Lewis G, Zammit S, Lawlor DA. The association of 25-hydroxyvitamin D3 and D2 with behavioural problems in childhood. PLoS One. 2012;7(7):e40097. doi: 10.1371/journal.pone.0040097.

19. Amori L, Wu HQ, Marinozzi M, Pellicciari R, Guidetti P, Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009;159(1):196-203. doi: 10.1016/j. neuroscience.2008.11.055.

20. Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211-6. doi: 10.1016/j. pbb.2011.01.020.

21. Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ. Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention. Behav Brain Funct. 2010;6:32. doi: 10.1186/1744-9081-6-32.

22. Kamal M, Bener A, Ehlayel MS. Is high prevalence of vitamin D deficiency a correlate for attention deficit hyperactivity disorder? Atten Defic Hyperact Disord. 2014;6(2):73-8. doi: 10.1007/s12402-014-0130-5.

23. Almeras L, Eyles D, Benech P, Laffite D, Villard C, Patatian A, et al. Developmental vitamin D deficiency alters brain protein expression in the adult rat: implications for neuropsychiatric disorders. Proteomics. 2007;7(5):769-80. doi: 10.1002/ pmic.200600392.

24. Morales E, Julvez J, Torrent M, Ballester F, Rodriguez- Bernal CL, Andiarena A, et al. Vitamin D in Pregnancy and Attention Deficit Hyperactivity Disorder-like Symptoms in Childhood. Epidemiology. 2015;26(4):458-65. doi: 10.1097/ ede.0000000000000292.

25. Rucklidge JJ, Johnstone J, Gorman B, Boggis A, Frampton CM. Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement. Prog Neuropsychopharmacol Biol Psychiatry. 2014;50:163-71. doi: 10.1016/j.pnpbp.2013.12.014.

26. Tanaka Y, Marumo T, Omura T, Yoshida S. Relationship between cerebrospinal and peripheral S100B levels after focal cerebral ischemia in rats. Neurosci Lett. 2008;436(1):40-3. doi: 10.1016/j.neulet.2008.02.056.

27. Nardin P, Tortorelli L, Quincozes-Santos A, de Almeida LM, Leite MC, Thomazi AP, et al. S100B secretion in acute brain slices: modulation by extracellular levels of Ca(2+) and K (+). Neurochem Res. 2009;34(9):1603-11. doi: 10.1007/s11064- 009-9949-0.